Pharma BD Deal Intelligence
A modest $355M genomics bolt-on that quietly became the durable backbone of Abbott's companion-diagnostics franchise for two-plus decades.
Full analysis, sources & comparables →Abbott completes $355M acquisition of Vysis at $30.50/share (33% premium), gaining FISH probes for cancer and genetic disease testing including PathVysion…
Medtech Insight characterized the Vysis purchase as Abbott's beachhead into oncology DNA-probe testing, with FISH technology positioned to dominate emerging…
Vysis CLL FISH Probe Kit became the first FDA-approved CLL prognostic FISH panel — direct downstream validation of the 2001 Vysis acquisition's strategic…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
$30.50/share cash (33% premium). Genomic disease management/FISH probes — became core of Abbott Molecular oncology dx franchise.
A modest $355M genomics bolt-on that quietly became the durable backbone of Abbott's companion-diagnostics franchise for two-plus decades.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Abbott Laboratories / Vysis Inc. (this deal) | 2001 | $355M | 79 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| Abbott Laboratories / St. Jude Medical | 2016 | $30.5B | 82 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Abbott Laboratories / Genentech, Inc. (Roche Group) | 2007 | — | 79 |
← Browse all deals · How we score deals
More: 2001 deals · Abbott Laboratories deals